Reappraisal of GIK in Acute STEMI by Pre-hospital Administration

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is:

1. to assess whether pre-hospital glucose-insulin-potassium (GIK) administration in acute STEMI patients would reduce infarct size and ischemia/reperfusion damage using comprehensive tissue characterization by cardiovascular magnetic resonance (CMR) at an early post-infarction phase.

2. to explore the putative cardioprotective mechanisms of pre-hospital GIK administration

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire Vaudois
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

1. Patients with the diagnosis of acute STEMI

2. age≥ 18

3. informed consent for study participation.

Exclusion Criteria evaluated during ambulance transport to primary PCI center:

1. end-stage renal failure requiring dialysis,

2. prior MI or coronary revascularization (PCI or CABG),

3. active malignances,

4. Pregnancy,

5. Hemodynamic instability (systolic blood pressure <100mmHg or significant pulmonary congestion defined as O2 saturation <90% on ambient air at pulso-oxymetry)

Exclusion Criteria evaluated after hospital admission at the primary PCI center (all patients will be re-evaluated for study continuation):

1. total ischemic time more than 8 hours (from symptoms onset to infarct-related artery mechanical re-opening)

2. evidence at diagnostic angiograms of TIMI flow-grade >1 of infarct-related artery or significant epicardial collaterals to the ischemic myocardium at risk (Rentrop flow-grade >1),

3. moderate-to-severe renal failure (estimated glomerular filtration rate < 30 ml/min/1.73 m2 by Cockcroft-Gault formula) and

4. urgent CABG.